These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17370923)

  • 1. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
    Al-Kali A; Ozer H
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
    Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
    J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
    Lyman GH
    J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
    Lyman GH; Kleiner JM
    Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment in oncology clinical practice. From risk factors to risk models.
    Lyman GH
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
    Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
    Jolis L; Carabantes F; Pernas S; Cantos B; López A; Torres P; Funes C; Caballero D; Benedit P; Salar A;
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):513-21. PubMed ID: 23730920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
    Zelenetz AD
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
    Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
    Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
    J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
    J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.